Study detail
Recruiting
Patisiran-LNP Pregnancy Surveillance Program
Alnylam Pharmaceuticals
Summary
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Eligibility
- Age range
- Not specified
- Sex
- Female
- Healthy volunteers
- No
Detailed criteria
Inclusion Criteria: * Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy Exclusion Criteria: * There are no exclusion criteria for participation in this program.
Locations (7)
- Clinical Trial SiteIowa City, Iowa
- Clinical Trial SiteNantes
- Clinical Trial SiteMünster
- Clinical Trial SitePavia
- Clinical Trial SiteGroningen
- Clinical Trial SiteLisbon